Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

Biomarker testing has the potential to improve patient outcomes significantly, but its high cost means it's not accessible to ...

A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...

Kettering, is hoping the third time's the charm on her effort to require private insurers to cover "biomarker" medical testing and thereby improve health outcomes in Ohio and cut down on personal ...

Alzheimer’s disease, the most common form of dementia affecting more than three million Americans a year, has proven difficult to diagnose in earlier stages. But detecting and treating the condition ...

House Bill 8, has been introduced in Ohio with the goal of expanding private insurance and Medicaid coverage for biomarker ...

Study highlights concerns about premature adoption of preeclampsia screening tests, emphasizing the need for clinical utility ...

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

Biomarker testing has the potential to improve patient outcomes significantly, but its high cost means it's not accessible to everyone.

Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms ...